Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail)

v3.4.0.3
Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Accrued expenses:    
Professional fees $ 749 $ 382
Salaries, bonuses and related benefits 762 2,492
Ovamed manufacturing rights - short term component 1,500 1,500
Research and development 746 810
Dr. Falk Pharma milestone 2,828 2,717
COH upfront fee for sponsored research for PepVax (see Note 6) 1,007 0
Accrued lease costs for abandoned properties 146 146
Other 521 523
Total accrued expenses 8,259 8,570
Other long-term liabilities:    
Long-term accrued lease costs for abandoned properties 17 91
Deferred rent 2,399 493
Total other long-term liabilities $ 2,416 $ 584